ANGELA GARRARD: Open Payments
NPI 1770981458 · GADSDEN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,939 in 175 payments from 15 companies in 2025. Trend: 2023 $2,967 · 2024 $3,914 · 2025 $2,939
Food & beverage: $2,939
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 38 | $558 |
| Alkermes, Inc. | 19 | $365 |
| Otsuka America Pharmaceutical, Inc. | 18 | $346 |
| Supernus Pharmaceuticals, Inc. | 13 | $268 |
| Tris Pharma Inc | 17 | $241 |
| ABBVIE INC. | 14 | $224 |
| Corium, LLC | 10 | $175 |
| Axsome Therapeutics, Inc. | 14 | $174 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Lundbeck LLC | 5 | $118 |
Products named: CAPLYTA, REXULTI, ARISTADA, Qelbree, Dyanavel XR, VRAYLAR, Azstarys, Auvelity.
Industry payments across AL — which companies pay providers there.
